Replies to post #266951 on Avid Bioservices Inc (CDMO)

[biopharm]

David Carbone : Peregrine Pharmaceuticals KOL and IASLC President:



2016 Latin American Lung Cancer Conference (LALCA)
August 25 - 27 2016 | Panama City, Panama | Contact: [e-mail]


https://www.iaslc.org/events/2016-latin-american-lung-cancer-conference-lalca

-----------

just a couple of the David Carbone appearances... but PS Targeting could come from other AZ directions as well...



Immunotherapy in Non-Small Cell Lung Cancer
Location: , Riu Plaza Panama, Panama
Chairs: Ana Oton, USA, Eduardo Richardet, Argentina,

Immunotherapy: Making it in a Simple Language
Predictive Assays for Immunotherapy - Fred Hirsch, USA
Clinical Trials with Anti-PD-1 - Luis E. Raez, USA
Clinical Trials with Anti-PDL-1 Inhibitors - Clarissa Mathias, Brazil
Other Immunotherapy Pathways - CTL4 and Others - David Carbone, USA
Questions and Answers


Novel Therapies Targeting Lung Cancer Pathways
Location: , Riu Plaza Panama, Panama
Chairs: Paul Bunn, USA, ,

RET/BRAF - Shirish Gadgell, USA
MET and MET Exon 14 Skipping - Paul Bunn, USA
Repair Inhibitors - Miguel Villalona, USA
NF-1 - David Carbone, USA
ROS-1
Questions and Answer Period

http://lalca2016.iaslc.org/program/scientific-program/

---------------

CTL4
http://www.ncbi.nlm.nih.gov/pubmed/27045021

EGFR
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=122606329